Nieuwenhuysen, E. V., Michels, J., Kim, H. S., Moreno, V., Colombo, N., Ottevanger, P. B., O'Cearbhaill, R. E., Perets, R., Reyners, A. K., Yoo, S., Wang, B., Brouwer, J., Cristea, M. C., Costigan, N., Peterman, M. J., Barnes, B., Lowy, I., Miller, E., Huang, G. S., Uldrick, T. S. (2026). A phase 1/2 study of ubamatamab (REGN4018), a MUC16×CD3 bispecific antibody, administered alone or in combination with cemiplimab in a low-grade serous ovarian cancer cohort: Trial in progress.. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2026.44.16_suppl.tps5638